Evidence map›Paper›PMID 42162053›Full record

ArticleScientific reports2026

Serum TIMP-1 concentrations are associated with cancer incidence and cancer-related mortality in a population-based cohort.

M T Nieminen, E Brandt, A S Havulinna, O Kambur, T Tervahartiala, T Zeller, S Blankenberg, V Salomaa, T Sorsa, P J Pussinen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

M T NieminenOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
E BrandtOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
A S HavulinnaInstitute for Molecular Medicine Finland, FIMM-HiLIFE, Helsinki, Finland.
O KamburSchool of Medicine, Institute of Dentistry, University of Eastern Finland, Kuopio, Finland.
T TervahartialaOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
T ZellerClinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
S BlankenbergClinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
V SalomaaDepartment of Medicine, University of Turku, Turku, Finland.
T SorsaOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
P J PussinenOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
A SalminenOral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. aino.m.salminen@helsinki.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is regulated by matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs); however, their utility as cancer biomarkers remains unclear. We investigated the associations of serum MMP-8, TIMP-1, and the MMP-8/TIMP-1 ratio with prevalent and incident cancer in 8448 individuals aged 25-74 years from the FINRISK97 cohort. Participants were followed for incident cancer (n = 1618) for 26 years through the Finnish Cancer Registry. Serum MMP-8 and TIMP-1 concentrations were measured at baseline using immunoassays. Serum TIMP-1 levels were significantly higher in individuals with prevalent and incident cancer, including colorectal and lung cancer, whereas lower MMP-8 levels were observed in colorectal and prostate cancer. Accordingly, the MMP-8/TIMP-1 ratio was reduced in individuals with incident cancer. In age-stratified models adjusted for sex, smoking, and BMI, elevated TIMP-1 levels were strongly associated with incident cancer in participants aged 55-64 years (HR, 95% CI 6.36, 2.50-16.16) and ≥ 65 years (6.23, 1.67-23.21), and with cancer mortality (29.7, 8.25-106 and 18.4, 3.64-93.6). MMP-8 and the MMP-8/TIMP-1 ratio showed weaker associations with incident cancer and cancer mortality only in the 45-54-year age group. These findings support TIMP-1 as a potential biomarker for cancer risk and mortality.

Indexed as

Matrix Metalloproteinase 8NeoplasmsRegistriesTissue Inhibitor of Metalloproteinase-1AdultAgedBiomarkers, TumorCohort StudiesFemaleFinlandHumansIncidenceMaleMiddle AgedTumor MicroenvironmentBiomarkers, TumorMatrix Metalloproteinase 8MMP8 protein, humanTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1BiomarkerCancerMatrix metalloproteinase 8Tissue inhibitor of matrix metalloproteinase 1Tumor

Identifiers

PMID42162053
PMCPMC13392385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.